Study on anti-inflammatory effect of peptides-conjugated alumina nanoparticle on allergic rhinitis mice model

Li Li; Jing Wang; Seyyed Shamsadin Athari; Chao-Wu Jiang

doi:10.15586/aei.v51i3.819

Li Li

Faculty of Pharmacy, Guangxi University of Chinese Medicine, Nanning, China.

Jing Wang

Department of Otorhinolaryngological, Dezhou Second People’s Hospital, Dezhou, China.

Seyyed Shamsadin Athari

Department of Immunology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.

Chao-Wu Jiang

Department of Otolaryngology Division I, The First Affiliated Hospital of Kunming Medical University, Kunming, China.

Keywords

Allergy, Nanoparticle, Peptide, Rhinitis

Abstract

Allergic rhinitis (AR) is a common atopic problem in which immune response to the environmental factors leads to clinical symptoms. Helicobacter pylori neutrophil-activating protein (HP-NAP) as a peptide attenuates Th2 response and stimulates Th1 activation and mucus adhesion promoting protein (MapA) as a cell-surface protein binds to mucus. This study evaluated the effect of HP-NAP and MapA conjugated with alumina nanoparticle on AR. HP-NAP and HP-NAP with MapA were conjugated to alumina nanoparticle and two separate nanoparticles were produced. The AR mice were treated with these and HP-NAP in peptide form. The AR symptoms, gene expression of mucus, levels of IL-33 and IL-4, and total and ovalbumin (OVA)-specific IgE levels were evaluated. Nasal rubbing, sneezing, gene expression of mucus, and IL-33 and IL-4 levels, and OVA-specific and total IgE were decreased in three treated groups compared to AR, and there was a significant decrease in the symptoms in AR-H-M-A group (P < 0.05) when compared to the other treated groups. HP-NAP has a controlling effect on AR, and in nanoparticle-conjugated form it can strongly attach to the airway’s mucus via MapA. Therefore, cooperation of HP-NAP-alumina with MapA can produce an effective and applicable treatment for AR.

Abstract 120 | PDF Downloads 135 HTML Downloads 28 XML Downloads 3

References

1. Frank Schuler CF Iv, Montejo JM. Allergic rhinitis in children and adolescents. Immunol Allergy Clin North Am. 2021;41(4):613–25. 10.1016/j.iac.2021.07.010

2. Masoume Athari S, Mehrabi Nasab E, Shamsadin Athari S. Study effect of Ocimum basilicum seeds on mucus production and cytokine gene expression in allergic asthma mice model. Rev Fr Allergol. 2018;58(7):489–93. 10.1016/j.reval.2018.08.003

3. Filho NAR, Satoris RA, Scala WR. Allergic rhinitis aggravated by air pollutants in Latin America: A systematic review. World Allergy Organ J. 2021;14(8):100574. 10.1016/j.waojou.2021.100574

4. Minelli C, Wei I, Sagoo G, Jarvis D, Shaheen S, Burney P. Interactive effects of antioxidant genes and air pollution on respiratory function and airway disease: A HuGE review. Am J Epidemiol. 2011;173(6):603–20. 10.1093/aje/kwq403

5. Zuo ZT, Ma Y, Sun Y, Bai CQ, Ling CH, Yuan FL. The protective effects of Helicobacter pylori infection on allergic asthma. Int Arch Allergy Immunol. 2021;182(1):53–64. 10.1159/000508330

6. Lankarani KB, Honarvar B, Athari SS. The mechanisms underlying Helicobacter pylori–mediated protection against allergic asthma. Tanaffos. 2017;16(4):251–9.

7. Jensen H, Roos S, Jonsson H, Rud I, Grimmer S, van Pijkeren JP, et al. Role of Lactobacillus reuteri cell and mucus binding protein A (CmbA) in adhesion to intestinal epithelial cells and mucus in vitro. Microbiology (Reading). 2014;160(Pt 4):671–81. 10.1099/mic.0.073551-0

8. Miyoshi Y, Okada S, Uchimura T, Satoh E. A mucus adhesion promoting protein, MapA, mediates the adhesion of Lactobacillus reuteri to caco-2 human intestinal epithelial cells. Biosci Biotechnol Biochem. 2006;70(7):1622–8. 10.1271/bbb.50688

9. Athari SS, Pourpak Z, Folkerts G, Garssen J, Moin M, Adcock IM, et al. Conjugated alpha-alumina nanoparticle with vasoactive intestinal peptide as a nano-drug in treatment of allergic asthma in mice. Eur J Pharmacol. 2016;791:811–20. 10.1016/j.ejphar.2016.10.014

10. Athari SM, Nasab EM, Athari SS. Animal model of allergy and asthma; protocol for researches. Protoc Exch. 2019;1:1–17. 10.21203/rs.2.13928/v1

11. Baraniuk JN. Pathogenesis of allergic rhinitis. J Allergy Clin Immunol. 1997;99(2):S762–S772. 10.1016/s0091-6749(97)70125-8

12. Ji KY, Jung DH, Pyun BJ, Kim YJ, Lee JY, Choi S, et al. Angelica gigas extract ameliorates allergic rhinitis in an ovalbumin-induced mouse model by inhibiting Th2 cell activation. Phytomedicine. 2021; 93:153789. 10.1016/j.phymed.2021.153789

13. Eschenbacher W, Straesser M, Knoeddler A, Li RC, Borish L. Biologics for the treatment of allergic rhinitis, chronic rhinosinusitis, and nasal polyposis. Immunol Allergy Clin North Am. 2020;40(4):539–47. 10.1016/j.iac.2020.06.001

14. Liu HC, Liao Y, Liu CQ. miR-487b mitigates allergic rhinitis through inhibition of the IL-33/ST2 signaling pathway. Eur Rev Med Pharmacol Sci. 2018;22(23):8076–83. 10.26355/eurrev_201812_16497

15. Stolarski B, Kurowska-Stolarska M, Kewin P, Xu D, Liew FY. IL-33 exacerbates eosinophil-mediated airway inflammation. J Immunol. 2010;185(6):3472–80. 10.4049/jimmunol.1000730

16. Johnston LK, Bryce PJ. Understanding interleukin 33 and its roles in eosinophil development. Front Med (Lausanne). 2017;4:51. 10.3389/fmed.2017.00051

17. Smith DE. IL-33: A tissue-derived cytokine pathway involved in allergic inflammation and asthma. Clin Exp Allergy. 2010;40(2):200–8. 10.1111/j.1365-2222.2009.03384.x

18. Nur Husna SM, Tina Tan HT, Md Shukri N, Mohd Ashari NS, Wong KK. Nasal epithelial barrier integrity and tight junctions disruption in allergic rhinitis: Overview and pathogenic insights. Front Immunol. 2021;12:663626. 10.3389/fimmu.2021.663626

19. Fukuoka A, Yoshimoto T. Barrier dysfunction in the nasal allergy. Allergol Int. 2018;67(1):18–23. 10.1016/j.alit.2017.10.006

20. Toppila-Salmi S, van Drunen CM, Fokkens WJ, Golebski K, Mattila P, Joenvaara S, et al. Molecular mechanisms of nasal epithelium in rhinitis and rhinosinusitis. Curr Allergy Asthma Rep. 2015;15(2):495. 10.1007/s11882-014-0495-8

21. Kumpitsch C, Koskinen K, Schopf V, Moissl-Eichinger C. The microbiome of the upper respiratory tract in health and disease. BMC Biol. 2019;17(1):87. 10.1186/s12915-019-0703-z

22. Choi S, Jung MA, Hwang YH, Pyun BJ, Lee JY, Jung DH, et al. Anti-allergic effects of Asarum heterotropoides on an ovalbumin-induced allergic rhinitis murine model. Biomed Pharmacother. 2021;141:111944. 10.1016/j.biopha.2021.111944

23. Artaç H, Vatansev H, Cimen D, Arslan D, Kaya F, Kayiş SA, et al. N-terminal-pro brain natriuretic peptide levels in children with allergic rhinitis. Turk J Med Sci. 2016;46(4):1130–4. 10.3906/sag-1502-143

24. Medina MA. 173 relationship between allergic rhinitis and dental–facial abnormalities. World Allergy Organ J. 2012;5(Suppl 2):S74. 10.1097/01.WOX.0000411930.26815.44

25. Al Ali A, Richmond S, Popat H, Toma AM, Playle R, Pickles T, et al. A three-dimensional analysis of the effect of atopy on face shape. Eur J Orthod. 2014;36(5):506–11. 10.1093/ejo/cjs107

26. Wraith DC, Krishna MT. Peptide allergen-specific immunotherapy for allergic airway diseases-state of the art. Clin Exp Allergy. 2021;51(6):751–69. 10.1111/cea.13840